32 year old Caucasian male
Switched to ALTUVIIIO April 2023
Peter presented to the clinic after experiencing numerous bleeding episodes and making frequent calls to the HTC.
Patient Information
Presented due to uncontrolled hemophilia A while on standard half-life prophylaxis therapy
- Over the last 3 years, he experienced hematuria, rectal bleeding, and hematoma of left leg muscle
- Target joints include left elbow, left knee, and right ankle
- Supraventricular tachycardia
- Sinus arrhythmia
- Kidney stones
- Hemophilia-related arthropathy
- Grandfather with severe hemophilia A
- 4 cousins with hemophilia A
- All aunts and mother are asymptomatic carriers
- BP: 147/104
- BMI: 31.1
- Left hip, left knee, and left elbow pain with active range of motion
- Modified PK conducted (Factor infusion and 1-hour post-infusion FVIII level)
- No official PK studies conducted due to Peter living 1+ hours away from clinic
- 1-hour FVIII level after SHL therapy was 166 (11/25/20)
- X-rays showed no acute pathology
Peter’s Path to High Sustained Factor Replacement Therapy, ALTUVIIIO
Diagnosis
- Peter was diagnosed with severe hemophilia A at 2 weeks of age due to a hematoma
After diagnosis
- At 7 years old, Peter presented at an HTC after experiencing numerous bleeding episodes
- Peter's bleeds were uncontrolled
- Frequent HTC calls, hospital visits, and bleeds. Reduced quality of life (experienced hematuria, rectal bleeding, and hematoma of left leg muscle over the last 3 years)
- Peter frequently needed analgesics to manage hemophilia-related pain
Before ALTUVIIIO
- Persistent breakthrough bleeding while on SHL, dosed every 3 days
Considering the switch
Provider and Peter discussed:
- History of noncompliance
- Frequent hospitalizations for emergent bleeds
Comprehensive care team and Peter felt that ALTUVIIIO could benefit him through1,2:
- Improved bleed protection
- Reduced treatment burden
- Improved pain and physical health
After ALTUVIIIO
Switched to ALTUVIIIO: April 2023
- Since starting ALTUVIIIO prophylaxis, Peter’s hemophilia remains well controlled. He is compliant, experiencing less hemophilia-related pain, and has not needed to call the HTC for emergent management
Do you have patients like Peter?
If so, it may be worth it to consider the following:
How good is good enough?
Do patients often say they’re doing fine despite experiencing multiple bleeds each year?
Choosing the right treatment
How would you discuss switching to a more appropriate treatment option, like ALTUVIIIO, with patients like Peter?
Unlocking high sustained factor levels
How could high sustained factor levels and once-weekly dosing with ALTUVIIIO help patients like Peter?
BMI=body mass index; BP=blood pressure; FVIII=Factor VIII; HTC=hemophilia treatment center; PK=pharmacokinetics; SHL=standard half-life.
Other ALTUVIIIO patients that made the switch!
Meet Otis
A 43 year old who works loading trucks and previously treated his moderate hemophilia A with an on-demand therapy.
Meet Noah
A 2 year old who was diagnosed with severe hemophilia A at birth due to a de novo mutation and was treating with prophylaxis therapy.
Indication
References: 1. ALTUVIIIO Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA. 2. von Drygalski A, et al. N Engl J Med. 2023;388(4):310-318.
